Novo Nordisk A/S
NONOF
$136.48
-$1.77-1.28%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 23.78% | 23.75% | 43.94% | 38.99% | 34.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.78% | 23.75% | 43.94% | 38.99% | 34.29% |
| Cost of Revenue | 29.15% | 22.47% | 27.39% | 45.47% | 32.11% |
| Gross Profit | 22.87% | 23.98% | 47.37% | 37.77% | 34.67% |
| SG&A Expenses | 3.09% | 8.03% | 29.72% | 20.37% | 32.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2,766.30% | 1,839.38% | 99.27% | -76.12% | 110.27% |
| Total Operating Expenses | 18.28% | 19.38% | 30.95% | 35.17% | 35.69% |
| Operating Income | 30.78% | 28.69% | 65.95% | 43.78% | 32.56% |
| Income Before Tax | 3.14% | 30.39% | 77.91% | 67.82% | 47.38% |
| Income Tax Expenses | 8.08% | 33.65% | 118.26% | 66.04% | 41.65% |
| Earnings from Continuing Operations | 1.92% | 29.58% | 69.83% | 68.26% | 48.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.92% | 29.58% | 69.83% | 68.26% | 48.88% |
| EBIT | 30.78% | 28.69% | 65.95% | 43.78% | 32.56% |
| EBITDA | 31.77% | 31.43% | 62.45% | 42.83% | 32.82% |
| EPS Basic | 2.66% | 30.73% | 71.46% | 70.02% | 50.49% |
| Normalized Basic EPS | 27.29% | 31.55% | 74.20% | 69.56% | 48.96% |
| EPS Diluted | 2.65% | 30.75% | 71.41% | 70.09% | 50.46% |
| Normalized Diluted EPS | 27.40% | 31.62% | 74.26% | 69.62% | 49.02% |
| Average Basic Shares Outstanding | -0.73% | -0.88% | -0.96% | -1.02% | -1.06% |
| Average Diluted Shares Outstanding | -0.83% | -0.95% | -1.00% | -1.06% | -1.09% |
| Dividend Per Share | 15.22% | -- | 65.07% | -- | 44.08% |
| Payout Ratio | -- | 0.21% | -- | -0.10% | -- |
